Melasma Clinical Trial
Official title:
The Efficacy of Combined Peels in Treatment of Melasma Using Modified Jessner's Solution With 20%Trichloroacetic Acid Versus 70%Glycolic Acid With 20% Trichloroacetic Acid : A Split-face Study
Melasma is a common acquired disorder of hyperpigmentation characterized by irregular light brown to dark brown patches of hyperpigmentation commonly affecting the face. The trunk and arms are also occasionally involved .
Key etiologic factors include a genetic predisposition, solar damage, barrier abnormalities,
and unique sensitivities to hormonal changes including pregnancy, oral contraceptives, and
hormone replacement therapy .Melasma can be divided into centrofacial, malar, and mandibular,
according to the pigment distribution on the skin. The hyperpigmented patches are usually
symmetrical and have a sharp irregular border.On wood's light examination three forms of
melasma exist (epidermal, dermal, and mixed). Epidermal & mixed types shows accentuation of
pigmentation, while there is no change in dermal type The epidermal type is the most
responsive to treatment .Melasma is often difficult to treat, and the condition may be
refractory. Principles of therapy include protection from ultraviolet light, inhibition of
melanocyte activity and melanin synthesis, and the disruption and removal of melanin granules
.Many depigmenting agents and other therapies such as chemical peeling are used for treating
melasma, in the form of monotherapy or combined therapy .The most commonly used peeling
agents are alpha-hydroxy-acids, glycolic acid , Jessner solution, salicylic acid
resorcinol,trichloroacetic acid , pyruvic acid and phenol Several hypopigmenting agents such
as topical hydroquinone (2 to 4%) alone or in combination with tretinoin (0.05 to 0.1%) have
been used with differing results. Topical azelaic acid (15 to 20%) can be as efficacious as
hydroquinone. Kojic acid, alone or in combination with glycolic acid or hydroquinone, has
shown good results, due to its inhibitory action on tyrosinase. Chemical peeling is
apromising treatment for numerous pigmentary disorders as melasma.Which aim to remove the
melanin ,rather than the inhibition of melanocytes or melanogenesis by causing controlled
necrosis and subsequent regeneration of the epidermis ,apart from remodeling of collagen and
elastic fiberes in the dermis . The gold standard for chemical peeling agents is
trichloroacetic acid It is a traditional chemical substance which has been used for both
superficial and medium-depth as well as deep peelings.It is not expensive, stable, not
light-sensitive and does not need to be neutralized .Classic Jessner's solution is a
combination of different chemical substances, including salicylic acid(14gm),
resorcinol(14gm), lactic acid(14gm) and ethanol, which can be used either alone for
superficial peeling or in combination with other agents to make easier medium-depth
procedures. Dr.Max Jessner originally formulated this peel to reduce the concentration and
toxicity of each of the individual ingredients while increasing efficacy. Modified formula:
lactic acid(17%), salicylic acid(17%), citric acid(8%) and ethanol .It is preferred , to
avoid possible allergic reactions and hyperpigmentation problems, which may be created by
resorcinol, especially in skin types V and VI.Gary Monheit has popularized the combination
peel using the classic Jessner's solution combined with trichloroacetic acid , to achieve a
more uniform penetration and an excellent peel with a low, safe concentration of
trichloroacetic acid Glycolic acid it is one of the most frequently used superficial peeling
agent.
It is stable , not light sensitive, inexpensive and easy to administer. Generally it is safe;
scarring uncommon; persistent erythema and postpeel hyperpigmentation rarely seen.The depth
of a Glycolic acid peel is a function of the concentration,volume and duration of
application.Glycolic acid has been used in combination with trichloroacetic acid peels .70%
glycolic acid is applied to the skin for 2 minutes.This is then neutralized,followed by the
application of 35% trichloroacetic acid peels without any prior acetone scrub.This
combination is thought to produce greater neoelastogenesis and less inflammation than
Jessner/trichloroacetic acid combination.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05013801 -
A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma
|
N/A | |
Recruiting |
NCT06174545 -
Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma
|
N/A | |
Completed |
NCT01695356 -
Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma
|
Phase 4 | |
Recruiting |
NCT06278948 -
Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma
|
N/A | |
Not yet recruiting |
NCT05911698 -
Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.
|
N/A | |
Recruiting |
NCT05656833 -
Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma
|
N/A | |
Recruiting |
NCT04597203 -
Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial
|
N/A | |
Completed |
NCT02138539 -
Evaluation of an Herbal-Based De-Pigmenting System
|
Phase 4 | |
Recruiting |
NCT01661556 -
Clinical Trial of Hydroquinone Versus Miconazol in Melasma
|
Phase 4 | |
Completed |
NCT01001624 -
Melanil in the Treatment of Melasma
|
Phase 3 | |
Terminated |
NCT03415685 -
Lutronic PicoPlus Exploratory Clinical Trial
|
N/A | |
Recruiting |
NCT04765930 -
Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma
|
N/A | |
Completed |
NCT04137263 -
Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging
|
N/A | |
Recruiting |
NCT03686787 -
Oral Tranexamic Acid and Laser for Treatment of Melasma
|
Phase 4 | |
Completed |
NCT05969587 -
Cysteamine Compared to Hydroquinone in Melasma
|
Phase 3 | |
Completed |
NCT00500162 -
Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma
|
Phase 4 | |
Completed |
NCT00472966 -
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
|
Phase 4 | |
Completed |
NCT05884151 -
Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma
|
Phase 1 | |
Completed |
NCT05887219 -
Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma
|
Phase 1 | |
Recruiting |
NCT03308370 -
Platelet Rich Plasma in Treatment of Melasma
|
Phase 3 |